Aridis Pharmaceuticals logo

Aridis PharmaceuticalsNASDAQ: ARDS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 August 2018

Next earnings report:

30 December 2024

Last dividends:

N/A

Next dividends:

N/A
$4.46 K
-99%vs. 3y high
1%vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Thu, 21 Nov 2024 14:30:00 GMT
$0.00$0.00(0.00%)

Dividend

No data over the past 3 years
$300.00 K$300.00 K

Analysts recommendations

Institutional Ownership

ARDS Latest News

Aridis Provides Corporate Update
globenewswire.com24 June 2024 Sentiment: POSITIVE

LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
globenewswire.com24 June 2024 Sentiment: POSITIVE

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Zacks Investment Research13 July 2023 Sentiment: POSITIVE

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Zacks Investment Research21 June 2023 Sentiment: POSITIVE

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
PennyStocks01 June 2023 Sentiment: POSITIVE

Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Zacks Investment Research01 June 2023 Sentiment: POSITIVE

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

5 Hot Penny Stocks To Watch With Big News This Week
PennyStocks31 May 2023 Sentiment: POSITIVE

Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.

What type of business is Aridis Pharmaceuticals?

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

What sector is Aridis Pharmaceuticals in?

Aridis Pharmaceuticals is in the Healthcare sector

What industry is Aridis Pharmaceuticals in?

Aridis Pharmaceuticals is in the Biotechnology industry

What country is Aridis Pharmaceuticals from?

Aridis Pharmaceuticals is headquartered in United States

When did Aridis Pharmaceuticals go public?

Aridis Pharmaceuticals initial public offering (IPO) was on 14 August 2018

What is Aridis Pharmaceuticals website?

https://www.aridispharma.com

Is Aridis Pharmaceuticals in the S&P 500?

No, Aridis Pharmaceuticals is not included in the S&P 500 index

Is Aridis Pharmaceuticals in the NASDAQ 100?

No, Aridis Pharmaceuticals is not included in the NASDAQ 100 index

Is Aridis Pharmaceuticals in the Dow Jones?

No, Aridis Pharmaceuticals is not included in the Dow Jones index

When was Aridis Pharmaceuticals the previous earnings report?

No data

When does Aridis Pharmaceuticals earnings report?

The next expected earnings date for Aridis Pharmaceuticals is 30 December 2024